Annovis Bio Consensus Price Target Lowered by 16.67% to $10.71
The average one-year price target for Annovis Bio (NYSE:ANVS) has been revised to $10.71 / share as of September 11, 2026. This is a decrease of 16.67% from the prior estimate of $12.85 dated August 25, 2026. These figures represent aggregate analyst targets and do not constitute a recommendation by Fintel.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $7.07 to a high of $17.85 / share. The average price target represents an increase of 823.28% from the latest reported closing price of $1.16 / share as of September 14, 2026.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). For context, the company reported an actual EPS of -0.4 against an estimated EPS of -0.4624 for its latest earnings on August 14, 2026, with both actual and estimated revenue at $0.00. The stock has experienced a one-week price change of -16.55% from a baseline close of $1.39 on September 4, 2026, and a one-month price change of -37.30% from a baseline close of $1.85 on August 14, 2026.
Looking at target history, the mean target was $14.02 on June 30, 2026, before declining to $12.85 on August 5, 2026, and subsequently reaching $10.71 on September 15, 2026. This current mean target represents the observed twelve-month low mean, compared to the observed twelve-month high mean of $15.98 on May 14, 2026. The target change since the 90-day baseline date of June 9, 2026, is -23.64%.
In terms of analyst sentiment, the recommendation trend as of September 1, 2026, shows 2 strong buy, 6 buy, and 1 hold recommendations, which is identical to the distribution from August 1, 2026. Recent analyst actions include Roth Capital maintaining a Buy rating on August 28, 2026, and Canaccord Genuity maintaining a Buy rating on August 18, 2026.
Within the broader Biotechnology sub-industry, 25 companies are covered, with 10 experiencing raised targets, 10 experiencing lowered targets, and 5 remaining unchanged. The sub-industry median revision percent is 0.00%, with a median implied change percent of +116.17%. Peer companies focused on neurodegenerative therapies display varying target revisions and implied changes.
| Company | Target revision | Implied change |
|---|---|---|
| NeuroSense Therapeutics | 0.00% | -3.91% |
| Alterity Therapeutics Limited - Depositary Receipt | +21.61% | +128.44% |
| IGC Pharma | 0.00% | +1,380.41% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.